| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| 50mg | |||
| Other Sizes |
| Targets |
The primary target of MC-Val-Cit-PAB-clindamycin is the bacterial 50S ribosomal subunit, where clindamycin inhibits protein synthesis. In ADC applications, the conjugate targets cancer cells or other diseased cells via antibody-mediated recognition of cell surface antigens. The MC-Val-Cit-PAB linker is designed for cathepsin B-mediated cleavage, enabling intracellular payload release. The compound is described as having potent antitumor properties.
|
|---|---|
| ln Vitro |
MC-Val-Cit-PAB-clindamycin exhibits potent antitumor activity in vitro through the action of the clindamycin payload, which functions as a protein synthesis inhibitor. The conjugate demonstrates effective cell killing when incorporated into ADC constructs with appropriate targeting antibodies. The MC-Val-Cit-PAB linker enables efficient intracellular release following antibody-mediated internalization. Standard purity is ≥95-99.99%.
|
| ln Vivo |
In vivo, MC-Val-Cit-PAB-clindamycin demonstrates potent antitumor activity when used in ADC formats. The conjugate is designed for stability in systemic circulation while enabling targeted payload delivery and selective release within target cells. The clindamycin payload exerts its antiproliferative effects following intracellular release and ribosomal binding. The MC-Val-Cit-PAB linker system has been validated in multiple ADC platforms for effective in vivo performance.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for MC-Val-Cit-PAB-clindamycin typically involve assessing linker stability and payload release kinetics. Cathepsin B cleavage assays are performed by incubating the conjugate with recombinant cathepsin B at pH 5.5, followed by HPLC or LC-MS analysis to quantify clindamycin release over time. Ribosome binding assays may be used to confirm the retained activity of the clindamycin payload. Stability studies in plasma are conducted to evaluate conjugate integrity.
|
| Cell Assay |
In vitro cellular assays for MC-Val-Cit-PAB-clindamycin ADC conjugates involve treating antigen-positive and antigen-negative cell lines with varying concentrations (typically 0.001-100 nM range) for 72-120 hours. Cell viability is measured using standard assays including MTT, CellTiter-Glo, or resazurin-based methods. Internalization studies using fluorescently labeled constructs confirm antibody-mediated uptake. IC50 values are determined by fitting dose-response curves. Appropriate controls include naked antibody and free payload.
|
| Animal Protocol |
In vivo animal studies for MC-Val-Cit-PAB-clindamycin ADC conjugates typically use xenograft mouse models. Tumor-bearing mice are administered the ADC intravenously at doses ranging from 1-30 mg/kg, with schedules such as single dose, QD×5, or QW×2. Tumor growth inhibition is monitored over 2-4 weeks. Endpoints include tumor volume, body weight, and survival. Pharmacodynamic assessments may include measurement of target engagement and downstream biomarkers in tumor tissue.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of MC-Val-Cit-PAB-clindamycin conjugates follow typical ADC PK profiles. Following IV administration, the conjugate shows biphasic elimination with appropriate stability in circulation. The MC-Val-Cit-PAB linker provides controlled release characteristics. PK parameters including clearance, volume of distribution, and half-life are determined via ELISA for total antibody and conjugated antibody, and LC-MS/MS for free payload. Bioavailability is not applicable for IV administration.
|
| Toxicity/Toxicokinetics |
Toxicological data for MC-Val-Cit-PAB-clindamycin is characteristic of ADC linker-payload constructs. Clindamycin is an established antibiotic with known safety profiles. As a research chemical, standard laboratory safety precautions should be followed including PPE and use of a fume hood. Comprehensive toxicology including repeat-dose and genotoxicity studies would be required for clinical development but are not publicly available for this specific conjugate.
|
| References | |
| Additional Infomation |
MC-Val-Cit-PAB-clindamycin (CAS# 1639793-13-7) is a research-grade drug-linker conjugate for ADC development. It is not approved for clinical use. The compound represents an approach to repurpose antibiotics as ADC payloads for cancer therapy. The MC-Val-Cit-PAB linker is a well-characterized, cathepsin B-cleavable system widely used in ADC research. This conjugate enables investigation of clindamycin as a payload for targeted therapeutics. The compound is typically stored at -20degC under inert atmosphere.
|
| Molecular Formula |
C46H72CLN8O11S
|
|---|---|
| Molecular Weight |
980.63
|
| Exact Mass |
979.472
|
| CAS # |
1639793-13-7
|
| PubChem CID |
139035083
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.3
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
25
|
| Heavy Atom Count |
67
|
| Complexity |
1720
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
C([C@@H]1C[C@@H](CCC)C[N+]1(C)CC1C=CC(NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)CCCCCN2C(C=CC2=O)=O)=CC=1)(=O)N[C@@]([H])([C@]1([H])[C@@H]([C@H](O)[C@@H](O)[C@@H](SC)O1)O)[C@@H](Cl)C
|
| InChi Key |
KINAEBJVJLCQDX-DCAHZPCSSA-O
|
| InChi Code |
InChI=1S/C46H71ClN8O11S/c1-7-12-29-23-32(43(63)53-37(27(4)47)41-39(60)38(59)40(61)45(66-41)67-6)55(5,25-29)24-28-15-17-30(18-16-28)50-42(62)31(13-11-21-49-46(48)65)51-44(64)36(26(2)3)52-33(56)14-9-8-10-22-54-34(57)19-20-35(54)58/h15-20,26-27,29,31-32,36-41,45,59-61H,7-14,21-25H2,1-6H3,(H6-,48,49,50,51,52,53,56,62,63,64,65)/p+1/t27-,29+,31-,32-,36-,37+,38-,39+,40+,41+,45+,55?/m0/s1
|
| Chemical Name |
(2S,4R)-1-[[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl]-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidin-1-ium-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~110 mg/mL (~108.26 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.46 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.46 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.46 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0198 mL | 5.0988 mL | 10.1975 mL | |
| 5 mM | 0.2040 mL | 1.0198 mL | 2.0395 mL | |
| 10 mM | 0.1020 mL | 0.5099 mL | 1.0198 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
